Tarsus Pharmaceuticals, Inc. (TARS)

NASDAQ: TARS · USD

$72.0

+1.26 (+1.8%)· Recorded snapshot

Market cap	3.2B
Revenue (ttm)	606.3M
Net income (ttm)	-46.5M
EPS (ttm)	-$1.08
Shares out	43.9M
Volume	303,716
Beta	0.45

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 606.3M
Net income (ttm): -46.5M
EPS (ttm): -$1.08
Market cap: 3.2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-13.7

P25 n/aP50 n/aP75 n/a

ROIC-7.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All TARS indicators

Market & fundamental data

Available fields

220

Groups with data

Currency

USD

Showing 220 of 220 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001819790
Company name	Tarsus Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	87650L103
Earnings date	2026-11-10
Earnings time	amc
Employees	370
Employees change	47
Employees growth	14.55%
Enterprise value	$2.8B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2016
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-10-16
Is primary listing	Yes
Is SPAC	No
ISIN number	US87650L1035
Last 10-K release date	2026-02-23
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$3.2B
Market cap category	Mid-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$72.02
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	TARS
U.S. state	California
Website	https://tarsusrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-1.5%
EV/FCF	49.64x
EV/Sales	4.59x
FCF / EV yield	2.01%
FCF yield	1.78%
Forward EV/Sales	3.36x
Forward P/S	3.8x
P/(FCF - SBC) ratio	749.68x
P/(OCF - SBC) ratio	140.57x
P/B ratio	8.83x
P/FCF ratio	56.09x
P/OCF ratio	42.36x
P/S ratio	5.18x
Price / tangible book value	9.24x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-8%
EBITDA margin	-7.62%
FCF margin	9.24%
Gross margin	82.67%
Operating margin	-8%
Pretax margin	-6.49%
Profit margin	-7.67%
Profit per employee	$-125,611
Revenue per employee	$1.6M
ROA	-5.48%
ROA (5Y)	-18.56%
ROCE	-11.15%
ROE	-13.68%
ROE (5Y)	-38.15%
ROIC	-7.22%
SBC / revenue	8.55%
Tax / revenue	1.18%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	9
EPS growth years	2
Gross profit growth	103.02%
Gross profit growth (Q)	67.8%
Gross profit growth 5Y	103.47%
Net income growth quarters	8
Net income growth years	2
Revenue growth	105.17%
Revenue growth (Q)	69.41%
Revenue growth (QoQ)	7.32%
Revenue growth 3Y	264.7%
Revenue growth 5Y	61.35%
Revenue growth quarters	8
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-18.2M
Depreciation and amortization	$2.3M
EBIT	$-48.5M
EBITDA	$-46.2M
EPS	$-1.08
FCF per share	$1.28
Financing cash flow	$9.4M
Free cash flow	$56M
Free cash flow minus SBC	$4.2M
Gross profit	$501.3M
Income taxes	$7.1M
Investing cash flow	$23.8M
Net cash flow	$107.4M
Net income	$-46.5M
Operating cash flow minus SBC	$22.3M
Operating income	$-48.5M
Revenue	$606.3M
Stock-based compensation	$51.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	6.66
Book value per share	$8.01
Debt / equity	0.26
Debt / FCF	1.59
Interest coverage	-5.54
Long-term assets	$49.2M
Long-term liabilities	$88.7M
Net cash (debt)	$360.9M
Net cash / market cap	11.49%
Net cash growth	16.9%
Net debt / equity	-1.04
Net debt / FCF	-6.44
Piotroski F-Score	3
Property, plant and equipment	$30.4M
Shareholders' equity	$346.7M
Tangible book value	$339.8M
Tangible book value per share	$7.85
Total assets	$611.1M
Total cash	$449.7M
Total debt	$88.8M
Total liabilities	$264.4M
WACC	6.73%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.1
Current assets	$562M
Current liabilities	$175.8M
Current ratio	3.2
Inventory turnover	25.47
Net working capital	$-63.3M
Quick ratio	3.12
Working capital	$386.2M
Working capital turnover	1.57

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-7.95%
Dividend yield	0%
Shareholder yield	-7.95%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$67.43
1D price change	1.78%
1M price change	-5.15%
1M total return	-5.15%
1W price change	1.07%
1W total return	1.07%
1Y price change	5.32%
1Y return CAGR	5.32%
1Y total return	5.32%
20-day SMA	$71.82
200-day SMA	$67.79
3M price change	19.41%
3M total return	19.41%
3Y price change	421.73%
3Y return CAGR	73.42%
3Y total return	421.73%
50-day SMA	$75.07
50-day SMA vs 200-day SMA	50over200
52-week high	$91.53
52-week high date	2026-09-04
52-week low	$53.89
52-week low date	2026-07-15
5Y price change	160.68%
5Y return CAGR	21.12%
5Y total return	160.68%
6M price change	17.82%
6M total return	17.82%
All-time high	$91.53
All-time high date	2026-09-04
All-time low	$10.80
All-time low date	2022-05-09
Average true range (ATR)	$3.22
Average volume	980.4K
Beta (1Y)	0.23
Beta (2Y)	0.24
Beta (5Y)	0.45
Change from 52-week high	-21.32%
Change from 52-week low	33.64%
Change from all-time high	-21.57%
Change from all-time low	564.72%
Change from open	2.3%
Day's gap	-0.51%
Dollar volume	$21.9M
High price	$72.16
Low price	$70.40
Monthly RSI	58.01
Open price	$70.40
Position in 52-week range	92.05%
Premarket change	1.03%
Premarket close	$70.76
Premarket price	$71.49
Premarket volume	1.9K
Previous close	$70.76
Price vs 150-day SMA	6.46%
Price vs 20-day SMA	-0.05%
Price vs 200-day SMA	5.9%
Price vs 50-day SMA	-4.37%
Relative volume	0.31
Return from IPO open	341.85%
Return from IPO price	347.38%
RSI	48.53
Sharpe ratio	0.25
Sharpe ratio (3Y)	1.27
Sharpe ratio (5Y)	0.54
Sortino ratio	0.51
Sortino ratio (3Y)	2.2
Sortino ratio (5Y)	0.91
Volume	303.7K
Weekly RSI	52.43
YTD price change	-12.32%
YTD total return	-12.32%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	32.7M
Float percentage	74.61%
Shares change (QoQ)	1.02%
Shares change (YoY)	7.95%
Shares held by insiders	3.06%
Shares held by institutions	88.62%
Shares outstanding	43.9M
Short % of float	17.51%
Short % of shares	13.06%
Short ratio	7.3 days

Deeper analysis on TARS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this TARS report

Is a complete TARS research report available?

No complete published report is available for Tarsus Pharmaceuticals, Inc. (TARS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Tarsus Pharmaceuticals, Inc. (TARS)

Price

Financial snapshot

Fair-value bridge

Latest news · TARS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All TARS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TARS

Frequently asked questions